Q
Qiang Sun
Researcher at Peking Union Medical College Hospital
Publications - 107
Citations - 1523
Qiang Sun is an academic researcher from Peking Union Medical College Hospital. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 15, co-authored 101 publications receiving 896 citations.
Papers
More filters
Journal ArticleDOI
A multi-centre randomised trial comparing ultrasound vs mammography for screening breast cancer in high-risk Chinese women
S. Shen,Y. Zhou,Y. Xu,Bao Ning Zhang,X. Duan,R. Huang,B. Li,Y. Shi,Zhimin Shao,H. Liao,Jun Jiang,N. Shen,Jin Zhang,C. Yu,Hongchuan Jiang,S. Li,S. Han,Jing Ma,Qiang Sun +18 more
TL;DR: Ultrasound is superior to mammography for breast cancer screening in high-risk Chinese women and the costs of ultrasound, mammography, and combined modality were $7876, $45 253, and $21 599, respectively.
Journal ArticleDOI
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
Nadia Harbeck,Chiun-Sheng Huang,Sara A. Hurvitz,Dah-Cherng Yeh,Zhimin Shao,Seock-Ah Im,Kyung Hae Jung,Kunwei Shen,Jungsil Ro,Jacek Jassem,Qingyuan Zhang,Young-Hyuck Im,Marek Z. Wojtukiewicz,Qiang Sun,Shin-Cheh Chen,Rainer-Georg Goeldner,Martina Uttenreuther-Fischer,Binghe Xu,Martine Piccart-Gebhart +18 more
TL;DR: LUX-Breast 1 compared afatinib plus vinorelbine with trastuzumab plus vInorlbine for such patients with HER2-positive metastatic breast cancer with progression-free survival and overall survival, assessed in the intention-to-treat population.
Journal ArticleDOI
Prognostic value of androgen receptor in triple negative breast cancer: A meta-analysis
TL;DR: AR positivity is associated with lower risk of disease recurrence in TNBC, and further clinical studies are warranted to clarify its prognostic role on TNBC recurrence and survival.
Journal ArticleDOI
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
Junjie Li,Junjie Li,Ke-Da Yu,Ke-Da Yu,Da Pang,Changqin Wang,Jun Jiang,Suisheng Yang,Y Liu,Peifen Fu,Yuan Sheng,Guojun Zhang,Yali Cao,Qi He,Shude Cui,Xijing Wang,Guosheng Ren,Xinzheng Li,Shiyou Yu,Pengxi Liu,Xiang Qu,Jinhai Tang,Ouchen Wang,Zhimin Fan,Guoqin Jiang,Jin Zhang,Jiandong Wang,Hongwei Zhang,Shui Wang,Jianguo Zhang,Feng Jin,Nanyan Rao,Binlin Ma,Ping-qing He,Binghe Xu,Zhigang Zhuang,Jianfeng Wang,Qiang Sun,Xiaofeng Guo,Miao Mo,Zhimin Shao,Zhimin Shao +41 more
TL;DR: Capecitabine when added to 3 cycles of docetaxel followed by3 cycles of a 3-drug anthracycline combination containing cape citabine instead of fluorouracil significantly improved DFS in TNBC without new safety concerns.
Journal ArticleDOI
Diagnostic Performance of Indocyanine Green-Guided Sentinel Lymph Node Biopsy in Breast Cancer: A Meta-Analysis
TL;DR: ICG fluorescence-guided SLNB is viable for detection of lymph node metastases in breast cancer and large-scale randomized multi-center trials are necessary to confirm the results.